Your browser is no longer supported. Please, upgrade your browser.
Settings
EBS [NYSE]
Emergent BioSolutions Inc.
Index- P/E10.81 EPS (ttm)5.63 Insider Own2.70% Shs Outstand53.30M Perf Week-3.64%
Market Cap3.38B Forward P/E12.15 EPS next Y5.01 Insider Trans-10.37% Shs Float45.20M Perf Month-22.84%
Income305.10M PEG1.18 EPS next Q2.29 Inst Own84.10% Short Float7.69% Perf Quarter-47.74%
Sales1.56B P/S2.17 EPS this Y445.20% Inst Trans0.03% Short Ratio4.12 Perf Half Y-34.42%
Book/sh28.57 P/B2.13 EPS next Y-43.97% ROA14.30% Target Price105.57 Perf Year-23.44%
Cash/sh9.87 P/C6.16 EPS next 5Y9.20% ROE28.60% 52W Range58.79 - 137.61 Perf YTD-32.09%
Dividend- P/FCF10.88 EPS past 5Y24.00% ROI14.30% 52W High-55.78% Beta0.99
Dividend %- Quick Ratio2.10 Sales past 5Y26.00% Gross Margin67.40% 52W Low3.50% ATR3.18
Employees2200 Current Ratio3.20 Sales Q/Q78.20% Oper. Margin34.80% RSI (14)31.62 Volatility3.89% 4.15%
OptionableYes Debt/Eq0.56 EPS Q/Q632.00% Profit Margin24.90% Rel Volume1.15 Prev Close61.01
ShortableYes LT Debt/Eq0.55 EarningsApr 29 AMC Payout0.00% Avg Volume843.95K Price60.85
Recom2.00 SMA20-9.94% SMA50-25.50% SMA200-37.50% Volume965,314 Change-0.26%
May-05-21Downgrade Argus Buy → Hold
Apr-07-21Initiated The Benchmark Company Buy $150
Feb-24-21Upgrade Chardan Capital Markets Neutral → Buy $112
Feb-19-21Downgrade Chardan Capital Markets Buy → Neutral $112
Jan-08-21Downgrade Wells Fargo Overweight → Equal Weight $110
Sep-14-20Resumed JP Morgan Neutral $103
Jul-31-20Reiterated Chardan Capital Markets Buy $86 → $112
Sep-12-19Initiated Guggenheim Buy
Sep-04-19Upgrade Wells Fargo Market Perform → Outperform
Nov-02-18Upgrade Goldman Neutral → Buy
Aug-03-18Reiterated Chardan Capital Markets Buy $53 → $57
Jun-13-18Initiated Argus Buy $62
Apr-25-18Downgrade Wells Fargo Outperform → Market Perform
Jan-24-18Initiated Goldman Neutral
Jan-16-18Reiterated Chardan Capital Markets Buy $47 → $53
Jun-28-16Reiterated Singular Research Buy $44 → $40
Apr-15-16Initiated Chardan Capital Markets Buy $47
Mar-28-16Initiated Singular Research Buy $44
Feb-19-16Initiated Wells Fargo Outperform
May-15-14Initiated Summer Street Research Buy $35
May-07-21 05:18AM  
May-06-21 10:50PM  
07:14PM  
04:50PM  
04:40PM  
03:30PM  
02:35PM  
11:35AM  
11:08AM  
09:30AM  
09:00AM  
07:01AM  
06:30AM  
06:30AM  
May-05-21 10:58PM  
10:08PM  
07:45PM  
06:28PM  
04:59PM  
04:05PM  
04:00PM  
03:31PM  
01:50PM  
12:59PM  
11:30AM  
11:15AM  
10:50AM  
10:43AM  
06:10AM  
May-04-21 11:15PM  
10:50PM  
04:50PM  
04:40PM  
04:29PM  
03:00PM  
02:15PM  
10:55AM  
10:54AM  
10:15AM  
10:00AM  
10:00AM  
06:33AM  
06:30AM  
May-03-21 11:00PM  
09:52PM  
03:25PM  
01:40PM  
01:30PM  
01:04PM  
12:45PM  
11:10AM  
10:49AM  
10:39AM  
10:15AM  
09:35AM  
06:08AM  
May-02-21 10:15AM  
09:30AM  
May-01-21 06:33PM  
05:00PM  
11:00AM  
07:40AM  
Apr-30-21 10:50PM  
08:20PM  
08:01PM  
07:36PM  
07:00PM  
05:55PM  
02:35PM  
02:30PM  
02:03PM  
01:15PM  
12:45PM  
12:30PM  
11:40AM  
11:14AM  
11:00AM  
11:00AM  
10:45AM  
10:06AM  
10:05AM  
09:19AM  
09:00AM  
06:30AM  
05:31AM  
12:50AM  
Apr-29-21 11:02PM  
07:14PM  
05:45PM  
05:03PM  
04:55PM  
04:19PM  
04:13PM  
04:05PM  
01:15PM  
12:30PM  
11:35AM  
11:11AM  
11:00AM  
10:25AM  
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers ACAM2000, a smallpox vaccine; BioThrax, an anthrax vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; and Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; and Trobigard a combination drug-device auto injector product candidate. Further, the company is developing COVID-EIG and COVID-HIG potential treatments to COVID-19 disease; and FLU-IGIV for the treatment of Influenza A infection in hospitalized patients. Additionally, it provides contract development and manufacturing service that comprises development services, drug substance manufacturing, and drug product manufacturing in the pharmaceutical and biotechnology industries, as well as the governments and non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bailey SueDirectorMar 04Sale92.378,168754,47824,427Mar 08 06:30 PM
Havey AdamEVP, Business OperationsMar 01Option Exercise40.9037,2791,524,81258,335Mar 03 06:07 PM
Havey AdamEVP, Business OperationsMar 01Sale99.3037,2793,701,64738,190Mar 03 06:07 PM
Kramer RobertPresident and CEOFeb 08Option Exercise30.7945,3971,397,961171,607Feb 09 05:23 PM
Kramer RobertPresident and CEOFeb 08Sale120.0345,3975,449,002139,210Feb 09 05:23 PM
Kramer RobertPresident and CEOJan 21Option Exercise26.4521,900579,255161,110Jan 22 04:14 PM
Kramer RobertPresident and CEOJan 21Sale110.0321,9002,409,657139,210Jan 22 04:14 PM
Kramer RobertPresident and CEOJan 20Option Exercise26.452,23259,036141,442Jan 22 04:14 PM
Kramer RobertPresident and CEOJan 20Sale110.002,232245,520139,210Jan 22 04:14 PM
Kramer RobertPresident and CEOJan 15Option Exercise25.6219,026487,446158,236Jan 19 04:28 PM
Kramer RobertPresident and CEOJan 15Sale106.0119,0262,016,901139,210Jan 19 04:28 PM
El-Hibri FuadChairmanNov 10Option Exercise26.4519,391512,8921,143,379Nov 12 06:30 PM
El-Hibri FuadChairmanNov 10Sale88.2119,3911,710,4801,123,988Nov 12 06:30 PM
El-Hibri FuadChairmanNov 09Option Exercise26.4520,000529,0001,143,988Nov 12 06:30 PM
El-Hibri FuadChairmanNov 09Sale95.2620,0001,905,2001,123,988Nov 12 06:30 PM
El-Hibri FuadChairmanNov 03Option Exercise26.4520,000529,0001,143,988Nov 04 08:53 PM
El-Hibri FuadChairmanNov 03Sale90.7420,0001,814,8001,123,988Nov 04 08:53 PM
El-Hibri FuadChairmanNov 02Option Exercise26.4520,000529,0001,143,988Nov 04 08:53 PM
El-Hibri FuadChairmanNov 02Sale90.4420,0001,808,8001,123,988Nov 04 08:53 PM
El-Hibri FuadChairmanSep 24Sale98.8512,5351,239,0851,123,988Sep 25 07:00 PM
El-Hibri FuadChairmanSep 23Sale100.5813,0001,307,5401,136,523Sep 25 07:00 PM
El-Hibri FuadChairmanSep 17Sale100.6820,0002,013,6001,149,523Sep 18 06:25 PM
El-Hibri FuadChairmanSep 16Sale102.4820,0002,049,6001,169,523Sep 18 06:25 PM
El-Hibri FuadChairmanSep 10Sale102.6620,0002,053,2001,189,523Sep 11 09:21 PM
El-Hibri FuadChairmanSep 09Sale102.8020,0002,056,0001,209,523Sep 11 09:21 PM
SULLIVAN LOUIS WDirectorSep 02Option Exercise20.087,893158,49150,655Sep 04 08:08 PM
SULLIVAN LOUIS WDirectorSep 02Sale111.2228,4183,160,60642,762Sep 04 08:08 PM
Bailey SueDirectorAug 18Sale128.314,665598,56432,595Aug 19 05:08 PM
Harsanyi ZsoltDirectorAug 17Sale133.716,609883,66424,579Aug 18 09:12 AM
JOULWAN GEORGE ADirectorAug 11Sale124.116,000744,63526,771Aug 12 04:52 PM
Zoon Kathryn CDirectorAug 10Sale130.271,000130,27012,489Aug 11 04:43 PM
Richard RonaldDirectorAug 07Sale131.006,297824,9078,276Aug 11 04:46 PM
Richard RonaldDirectorJun 03Sale87.516,572575,1424,269Jun 05 04:36 PM
Bailey SueDirectorJun 03Sale87.505,322465,69137,260Jun 05 04:33 PM
Hauer Jerome MDirectorMay 26Sale85.154,385373,37310,188May 27 05:10 PM
Zoon Kathryn CDirectorMay 26Sale85.104,093348,32213,489May 27 05:07 PM
Harsanyi ZsoltDirectorMay 14Option Exercise18.643,43464,01028,367May 18 07:12 PM
Zoon Kathryn CDirectorMay 12Sale85.211,660141,45414,761May 14 04:30 PM
Harsanyi ZsoltDirectorMay 11Sale81.994,940405,02524,933May 13 07:47 PM
JOULWAN GEORGE ADirectorMay 11Sale85.192,000170,37129,950May 13 07:45 PM
APVO Aptevo Therapeutics Inc. daily Stock Chart
APVO [NASD]
Aptevo Therapeutics Inc.
Index- P/E- EPS (ttm)-9.17 Insider Own5.52% Shs Outstand3.86M Perf Week-13.28%
Market Cap108.12M Forward P/E- EPS next Y-5.25 Insider Trans0.00% Shs Float1.90M Perf Month-7.99%
Income-30.90M PEG- EPS next Q1.69 Inst Own66.60% Short Float7.00% Perf Quarter-31.77%
Sales4.30M P/S25.14 EPS this Y38.20% Inst Trans0.07% Short Ratio2.85 Perf Half Y111.13%
Book/sh4.29 P/B5.53 EPS next Y-68.80% ROA-52.70% Target Price- Perf Year366.73%
Cash/sh8.77 P/C2.70 EPS next 5Y- ROE-166.70% 52W Range4.62 - 60.00 Perf YTD-35.31%
Dividend- P/FCF- EPS past 5Y26.00% ROI- 52W High-60.48% Beta7.12
Dividend %- Quick Ratio- Sales past 5Y-33.70% Gross Margin- 52W Low413.33% ATR1.98
Employees58 Current Ratio3.30 Sales Q/Q- Oper. Margin- RSI (14)36.70 Volatility8.30% 6.98%
OptionableNo Debt/Eq1.51 EPS Q/Q36.10% Profit Margin- Rel Volume0.38 Prev Close24.94
ShortableYes LT Debt/Eq1.21 Earnings- Payout- Avg Volume46.61K Price23.71
Recom1.70 SMA20-8.43% SMA50-19.57% SMA200-3.15% Volume17,994 Change-4.93%
Nov-05-18Initiated Ladenburg Thalmann Buy
Oct-05-17Resumed Piper Jaffray Overweight $6
Apr-09-21 09:00AM  
Mar-31-21 08:00AM  
Feb-09-21 07:30PM  
Jan-11-21 08:00AM  
Jan-06-21 12:00PM  
Dec-19-20 01:45PM  
Dec-02-20 08:00AM  
Nov-20-20 07:37AM  
Nov-19-20 04:15PM  
Nov-16-20 08:00AM  
Nov-10-20 08:40AM  
Nov-09-20 09:00AM  
06:00AM  
Nov-08-20 11:15PM  
Nov-03-20 09:00AM  
Sep-01-20 09:00AM  
Aug-14-20 09:00AM  
Aug-06-20 09:00AM  
Jul-21-20 09:00AM  
Jun-30-20 12:00PM  
11:30AM  
Jun-29-20 09:00AM  
Jun-25-20 09:00AM  
Jun-10-20 09:00AM  
May-13-20 09:00AM  
Apr-14-20 09:00AM  
Mar-25-20 09:00AM  
Mar-16-20 09:00AM  
Feb-28-20 09:05AM  
08:59AM  
Jan-30-20 09:00AM  
Jan-13-20 08:00AM  
Dec-19-19 03:50PM  
Dec-06-19 09:00AM  
Nov-12-19 09:00AM  
Nov-08-19 09:00AM  
Nov-07-19 09:00AM  
Oct-04-19 07:32AM  
Oct-03-19 04:02PM  
04:02PM  
Sep-19-19 09:00AM  
Aug-09-19 09:00AM  
Aug-07-19 09:02AM  
Jul-25-19 04:32PM  
Jun-25-19 09:00AM  
May-09-19 09:00AM  
Apr-29-19 10:21AM  
Apr-26-19 08:31AM  
Apr-15-19 09:00AM  
Apr-11-19 12:26PM  
Apr-02-19 09:02AM  
Mar-25-19 09:02AM  
Mar-20-19 09:02AM  
Mar-18-19 09:00AM  
Mar-14-19 10:28AM  
Mar-07-19 09:13AM  
Mar-06-19 04:37PM  
Jan-07-19 08:30AM  
Jan-03-19 09:02AM  
Dec-21-18 09:00AM  
Dec-20-18 12:57PM  
Dec-13-18 09:02AM  
Dec-11-18 07:20AM  
Nov-20-18 09:00AM  
Nov-14-18 04:02PM  
Nov-09-18 12:00AM  
Oct-24-18 09:00AM  
Oct-10-18 08:40AM  
Sep-25-18 11:29AM  
Sep-05-18 11:36AM  
Aug-31-18 02:46PM  
Aug-09-18 09:00AM  
Aug-07-18 09:00AM  
Aug-06-18 08:10AM  
May-29-18 09:00AM  
May-15-18 07:40AM  
May-10-18 09:00AM  
May-08-18 09:02AM  
May-01-18 09:00AM  
Apr-30-18 07:50AM  
Apr-20-18 08:35PM  
Apr-16-18 09:02AM  
Mar-19-18 08:20AM  
Mar-13-18 09:02AM  
Mar-12-18 09:02AM  
Feb-27-18 09:02AM  
Jan-17-18 08:10AM  
Jan-11-18 09:04AM  
Jan-08-18 09:00AM  
Jan-03-18 08:17AM  
Dec-27-17 10:58AM  
Dec-19-17 09:05AM  
Dec-11-17 01:28PM  
09:02AM  
Nov-29-17 10:58AM  
Nov-28-17 07:02AM  
Nov-21-17 06:39PM  
Nov-14-17 04:02PM  
Nov-09-17 04:30PM  
Nov-01-17 11:50AM  
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1/1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It is also developing APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer; and other pre-clinical development stage therapeutics focused on hematologic and solid tumors. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TANG KEVIN C10% OwnerNov 06Buy22.73174,2773,961,8981,760,000Nov 06 04:47 PM
TANG KEVIN C10% OwnerNov 05Buy18.78625,72311,750,3071,585,723Nov 06 04:47 PM
TANG KEVIN C10% OwnerNov 04Buy14.35636,6759,137,026960,000Nov 06 04:47 PM